Beeline Medicines Announces Positive Topline Results from Global Phase 2 Study of Afimetoran in Systemic Lupus Erythematosus (GlobeNewswire) - Sep 9, 2026 - "Study met its primary endpoint, with afimetoran demonstrating higher SRI-4 response rates versus placebo at Week 48 (p-value <0.001 across all dose groups); Secondary endpoints demonstrated improvements consistent with the primary endpoint findings; Afimetoran was generally well tolerated, with a safety profile consistent with previous Phase 1 clinical trial experience and no new safety signals observed"
P2 data • Systemic Lupus Erythematosus
|